Alpha tocopheryl acetate - Osteoradionecrosis of the jaw

You are here : Home > Formulary Search > Alpha tocopheryl acetate - Osteoradionecrosis of the jaw

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Capsules
Oral suspension

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

Restrictions / Comments :

Important

FOR ORAL SURGEONS ONLY: Prevention: along with pentoxifylline 1 week before extraction and continue for 3 months (until good healing had been observed). For treatment to be continued long term until healing is observed.

Documentation

No records returned.

PAD Profile

ChemicalSubstance :

Alpha tocopheryl acetate

Indication :

Osteoradionecrosis of the jaw

Group Name :

Keywords :

Vitamin E

Brand Names Include :

Important Information :

osteonecrosis of the jaw, ORN, ONJ

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Alpha tocopheryl acetate is used to treat.

No records returned.

Other Drugs

Below are listed other drugs that are used to treat Osteoradionecrosis of the jaw.

Pentoxifylline

Committee Recommendations (1)

05 Feb 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.